▼ -22.67% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Medpace in the last 3 months. The average price target is $121.83, with a high forecast of $180.00 and a low forecast of $75.00. The average price target represents a -22.67% upside from the last price of $157.54.
The current consensus among 5 contributing investment analysts is to hold stock in Medpace. This rating changed within the last month from a Buy consensus rating.
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.